182 related articles for article (PubMed ID: 23335089)
1. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin.
Gee J; Bailey H; Kim K; Kolesar J; Havighurst T; Tutsch KD; See W; Cohen MB; Street N; Levan L; Jarrard D; Wilding G
Prostate; 2013 Jun; 73(9):970-8. PubMed ID: 23335089
[TBL] [Abstract][Full Text] [Related]
2. A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance.
Jarrard D; Filon M; Huang W; Havighurst T; DeShong K; Kim K; Konety BR; Saltzstein D; Mukhtar H; Wollmer B; Suen C; House MG; Parnes HL; Bailey HH
Prostate; 2021 Jan; 81(1):41-49. PubMed ID: 33095939
[TBL] [Abstract][Full Text] [Related]
3. Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial.
Miles FL; Goodman PJ; Tangen C; Torkko KC; Schenk JM; Song X; Pollak M; Thompson IM; Neuhouser ML
Nutrients; 2017 Apr; 9(4):. PubMed ID: 28417914
[TBL] [Abstract][Full Text] [Related]
4. Long-term vitamin D3 supplementation is more effective than vitamin D2 in maintaining serum 25-hydroxyvitamin D status over the winter months.
Logan VF; Gray AR; Peddie MC; Harper MJ; Houghton LA
Br J Nutr; 2013 Mar; 109(6):1082-8. PubMed ID: 23168298
[TBL] [Abstract][Full Text] [Related]
5. Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy.
Henning SM; Wang P; Said JW; Huang M; Grogan T; Elashoff D; Carpenter CL; Heber D; Aronson WJ
Prostate; 2015 Apr; 75(5):550-9. PubMed ID: 25545744
[TBL] [Abstract][Full Text] [Related]
6. Effects of vitamin D2-fortified bread v. supplementation with vitamin D2 or D3 on serum 25-hydroxyvitamin D metabolites: an 8-week randomised-controlled trial in young adult Finnish women.
Itkonen ST; Skaffari E; Saaristo P; Saarnio EM; Erkkola M; Jakobsen J; Cashman KD; Lamberg-Allardt C
Br J Nutr; 2016 Apr; 115(7):1232-9. PubMed ID: 26864127
[TBL] [Abstract][Full Text] [Related]
7. The correlation between zinc and insulin-like growth factor 1 (IGF-1), its binding protein (IGFBP-3) and prostate-specific antigen (PSA) in prostate cancer.
Daragó A; Sapota A; Matych J; Nasiadek M; Skrzypińska-Gawrysiak M; Kilanowicz A
Clin Chem Lab Med; 2011 Oct; 49(10):1699-705. PubMed ID: 21671822
[TBL] [Abstract][Full Text] [Related]
8. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence.
Yu H; Nicar MR; Shi R; Berkel HJ; Nam R; Trachtenberg J; Diamandis EP
Urology; 2001 Mar; 57(3):471-5. PubMed ID: 11248622
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
Lieberman R
Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
[TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer.
Schwartz GG; Hall MC; Stindt D; Patton S; Lovato J; Torti FM
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8680-5. PubMed ID: 16361554
[TBL] [Abstract][Full Text] [Related]
11. Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring.
Gilbert R; Metcalfe C; Fraser WD; Lewis S; Donovan J; Hamdy F; Neal DE; Lane JA; Martin RM; Tilling K
Eur J Cancer Prev; 2013 Mar; 22(2):121-5. PubMed ID: 22955340
[TBL] [Abstract][Full Text] [Related]
12. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients.
Mazzucchelli R; Montironi R; Santinelli A; Lucarini G; Pugnaloni A; Biagini G
Prostate; 2000 Sep; 45(1):72-9. PubMed ID: 10960845
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.
Liu G; Oettel K; Ripple G; Staab MJ; Horvath D; Alberti D; Arzoomanian R; Marnocha R; Bruskewitz R; Mazess R; Bishop C; Bhattacharya A; Bailey H; Wilding G
Clin Cancer Res; 2002 Sep; 8(9):2820-7. PubMed ID: 12231522
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer.
Kohli M; Kaushal V; Spencer HJ; Mehta P
Urology; 2003 Apr; 61(4):765-9. PubMed ID: 12670562
[TBL] [Abstract][Full Text] [Related]
16. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of biomarker modulation by fenretinide in prostate cancer patients.
Urban D; Myers R; Manne U; Weiss H; Mohler J; Perkins D; Markiewicz M; Lieberman R; Kelloff G; Marshall M; Grizzle W
Eur Urol; 1999; 35(5-6):429-38. PubMed ID: 10325501
[TBL] [Abstract][Full Text] [Related]
18. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
Friedlander TW; Weinberg VK; Small EJ; Sharib J; Harzstark AL; Lin AM; Fong L; Ryan CJ
Urol Oncol; 2012; 30(4):408-14. PubMed ID: 20884247
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy.
Bubley GJ; Balk SP; Regan MM; Duggan S; Morrissey ME; Dewolf WC; Salgami E; Mantzoros C
J Urol; 2002 Nov; 168(5):2249-52. PubMed ID: 12394769
[TBL] [Abstract][Full Text] [Related]
20. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis.
Shariat SF; Lamb DJ; Kattan MW; Nguyen C; Kim J; Beck J; Wheeler TM; Slawin KM
J Clin Oncol; 2002 Feb; 20(3):833-41. PubMed ID: 11821468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
